Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial (PRACTECAL-PRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03942354
Recruitment Status : Unknown
Verified May 2021 by Medecins Sans Frontieres, Netherlands.
Recruitment status was:  Recruiting
First Posted : May 8, 2019
Last Update Posted : May 13, 2021
University of Sussex
London School of Hygiene and Tropical Medicine
THINK TB & HIV Investigative Network
Wits Health Consortium (Pty) Ltd
Ministry of Public Health, Republic of Belarus
Ministry of Health, Republic of Uzbekistan
Information provided by (Responsible Party):
Medecins Sans Frontieres, Netherlands

Brief Summary:
PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

Condition or disease Intervention/treatment Phase
Multidrug Resistant Tuberculosis Drug: Bedaquiline Drug: Pretomanid Drug: Moxifloxacin Drug: Linezolid Drug: Clofazimine Drug: Directly observed therapy (DOT) Phase 2 Phase 3

Detailed Description:

Tolerability of drugs for TB is a complex and dynamic course for patients with drug resistance and can be affected by many different factors. A deeper understanding of the perspectives and experience of men and women participating in novel TB treatment trials will add to the understanding of the safety and efficacy of treatment.

TB-PRACTECAL is a multicentre, open label, phase 2-3 randomised controlled trial evaluating exclusively oral 6 months regimens containing bedaquiline, pretomanid, linezolid +/- moxifloxacin or clofazimine for the treatment of microbiologically confirmed pulmonary M/XDR-TB. It is registered with the with identifier number NCT02589782. The trial aims to recruit 630 adults from two sites in Uzbekistan (Nukus and Tashkent) and one site each from Belarus and South Africa.

The TB-PRACTECAL trial assumes that even if the investigational arms would have non-inferior efficacy and safety compared to the standard of care outcomes, patients would prefer a shorter, exclusively oral regimen with a lower pill count. This study therefore aims to describe patient experiences (i.e. the quality of the treatment experience as opposed to the quantity of treatment or the amount of time spent on it).

The PRACTECAL-PRO sub-study aims to answer the question: "What are the perceptions, expectations and experiences of novel TB treatment for adult patients participating in a six-month regimen clinical trial in Uzbekistan, South Africa and Belarus?"

The objectives for the analysis are:

  • To compare baseline scores between trial patients (all interventional arm patients plus standard of care patients) with healthy controls.
  • To assess changes in scores over time in patients on the intervention arms and patients on the standard of care arm.
  • To assess the utility of the SF 12 and SGRQ in a TB clinical trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Actual Study Start Date : September 1, 2019
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : October 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Arm Intervention/treatment
Experimental: Intervention arm
A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.
Drug: Bedaquiline
Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
Other Names:
  • Sirturo
  • R207910
  • TMC207

Drug: Pretomanid
Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
Other Name: PA-824

Drug: Moxifloxacin
Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
Other Name: Avelox, BAY 12-8039

Drug: Linezolid
Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
Other Name: Zyvox

Drug: Clofazimine
Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
Other Name: Lamprene

Active Comparator: Standard therapy
72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.
Drug: Directly observed therapy (DOT)
Standard therapy

Primary Outcome Measures :
  1. Change in St George's respiratory questionnaire SGRQ survey questionnaire from baseline to 12 months [ Time Frame: 12 months ]
    To assess the quality of life (QoL) of trial patients from baseline to 12 months: both those treated in the investigational arms and the standard of care arm. For the SGRQ, a change of 4 points is suggested to indicate a clinically significant change, although the questionnaire was developed with patients who had COPD rather than TB. In the sub-study with a relatively small sample we cannot be confident about whether a change of 4 points represents a similarly significant change, but we will be mindful to assess this possibility. Ultimate aim is to determine whether disease-specific patient quality of life scores improve in investigational arm patients from baseline to successful completion of treatment.

  2. Changes in Short form 12 survey questionnaire (patient satisfaction and experience) from baseline to 12 months [ Time Frame: 12 months ]
    Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). Ultimate aim is to determine whether disease-specific patient satisfaction scores improve in investigational arm patients from baseline to successful completion of treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients recruited into the TB-PRACTECAL trial in the approved sites OR
  • Local healthy-controls of a similar profile in terms of age and gender aged ≥18 years AND
  • Literate in the study questionnaire languages
  • Able to sign the sub-study informed consent form after agreeing to the additional interviews and completion of questionnaires.

Exclusion Criteria:

  • TB patients excluded from TB-PRACTECAL clinical trial
  • Healthy volenteers with co-morbidities
  • Healthy volenteers found to have TB

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03942354

Layout table for location contacts
Contact: Nicola James, MSc +44 2070674255
Contact: Charlotte Batts

Layout table for location information
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital Recruiting
Minsk, Belarus
Contact: Ernest Nshimiyimana, MD    +375336486008   
Principal Investigator: Varvara Solodovnikova, MD         
South Africa
Doris Goodwin Hospital Recruiting
Pietermaritzburg, KwaZulu Natal, South Africa
Contact: Odette van Amsterdam    033 398 0054   
Principal Investigator: Ronelle Moodliar, MBBS, MMed         
THINK Clinical Trial Unit, Hillcrest Recruiting
Durban, KwaZulu-Natal, South Africa, 3650
Contact: Seshni Moorgas    0317771009   
Principal Investigator: Ronelle Moodliar, MBBS,MMed         
Helen Jospeh Hospital Recruiting
Johannesburg, South Africa
Contact: Sharon Motlhako    +27 11 276 8800   
Principal Investigator: Mohammed Rassool, MBChB         
Republican TB Hospital No. 2 Recruiting
Nukus, Karakalpakstan, Uzbekistan
Contact: Soe Moe, MD    +998939200344   
Principal Investigator: Tigay N Zinaida, MD         
Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital Recruiting
Tashkent, Uzbekistan
Contact: Pei Sun Aw, MD    +998 933881121   
Principal Investigator: Irina Liverko, MD         
Sponsors and Collaborators
Medecins Sans Frontieres, Netherlands
University of Sussex
London School of Hygiene and Tropical Medicine
THINK TB & HIV Investigative Network
Wits Health Consortium (Pty) Ltd
Ministry of Public Health, Republic of Belarus
Ministry of Health, Republic of Uzbekistan
Layout table for investigator information
Principal Investigator: Beverley Stringer MSF
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medecins Sans Frontieres, Netherlands Identifier: NCT03942354    
Other Study ID Numbers: PRACTECAL-PRO
First Posted: May 8, 2019    Key Record Dates
Last Update Posted: May 13, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medecins Sans Frontieres, Netherlands:
Quality of life, drug-resistant tuberculosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis, Multidrug-Resistant
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Synthesis Inhibitors
Antitubercular Agents
Anti-Inflammatory Agents
Leprostatic Agents